Could a targeted drug shrink recurrent endometrial tumors?

NCT ID NCT00087685

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase II trial tests whether the drug RAD001 can shrink or slow the growth of tumors in people with recurrent endometrial cancer. Participants take RAD001 daily by mouth. The study measures how many patients have their tumors shrink or stay stable, and also tracks side effects. It includes people who have had up to two prior chemotherapies for their recurrent disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RAD001 (everolimus)
What this could lead to
If successful, this could offer a new treatment option for people with recurrent endometrial cancer who have limited chemotherapy choices.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply broadly. The drug may cause side effects and might not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.